Articular pain is an important socioeconomic problem. For example, the prevalence of knee pain in the 40 to 79 year old community of the United Kingdom is about 25.3% (
7). The exact etiology is not fully understood. Infectious, metabolic, autoimmune, traumatic, and, in particular, degenerative processes may all play a role, causing an initial inflammatory response that is characterized by increased local production of pro-inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 (
8,
9). Cytokines are small proteins produced by either immune (macrophages or helper T-cells) or non-immune cells (endothelial cells, Schwann cells, and their derivatives such as satellite cells in the dorsal root ganglion [DRG]). Under inflammatory conditions, cytokines are released and act on a number of different cells, serving as communicators and often as part of a cytokine cascade. Furthermore, pro-inflammatory cytokines maintain an up-regulated inflammatory response. There is increasing evidence that they also play an important role in the generation and maintenance of pain (
10,
11) thus contributing to the loss of normal function in all phases of articular disorders. Joints are innervated by the articular branches of the nerves that supply the muscles acting upon them. Numerous simple nerve endings are located at the attachments of joint capsules and ligaments and are believed to be terminals of unmyelinated and thinly myelinated nociceptive axons. The articular nerves contain Aβ-, Aδ, and C-fibers. Free nerve endings have been found in all joint structures other than normal cartilage (
12). The generation of pain from the inflammatory process is not simply due to conduction of nociceptive stimuli through the conventional channels. Although, research has shown that there is peripheral sensitization of primary afferent nociceptors in the joint itself, yet there is also a second relevant mechanism. Cytokines may also be transported to the DRG, crossing the blood-nervous-system barrier to reach the dorsal horn of the spinal cord, causing activation of microglia and astrocytes (
13). This factor may potentially frustrate attempts to treat joint pain by ablation of afferent nerves. Osteoarthritis (OA) represents the most frequent form of joint disease, and is common in patients over 60 years of age. It has been associated with the allostatic load of the immune system (
14), and indeed, mildly elevated C-reactive protein (CRP) levels have been demonstrated in patients with early OA (
15). Especially in the early stages, OA produces pain and a reduced range of motion of the affected joint. The disease typically has a chronic, fluctuating course leading to changes in the structure of the synovia, cartilage, and subjacent bone. Experimental data have shown that OA is a result of an episode of mild inflammatory processes within the joint (
16) that lead to high levels of pro-inflammatory cytokines (
8-
10,
17). Destruction of articular cartilage and remodelling of subchondral bone are prominent features of the later stages of the disease (
18). Most studies on pain in OA have involved the knee joint. It has recently been suggested that magnetic resonance imaging (MRI) findings such as synovial hypertrophy, synovial effusions, and subchondral bone-marrow edema are found more frequently in painful than in non-painful knee joints with OA (
19). The management of OA pain includes a myriad of conservative treatments with limited efficacy. Infiltrations with corticosteroids and viscosupplementation are widely used, but reportedly have short-lasting (
20) or no effects; their use is often contraindicated, especially in small joints (
19). The more recent method for treating OA by the means of anti-inflammatory drugs directed at cytokines to prevent the progression of structural changes of the joint has been disappointing for a number of reasons, and needs further investigation in regards to delivery form and reduction of toxicity (
10). For many patients, the current treatment options for OA are thus unsatisfactory, and this leads to abuse of non-steroidal anti-inflammatory drugs, expensive conservative therapies, and repeated corticosteroid infiltrations. No clear consensus exists in regards to the timing and indications for major surgical procedures for OA (
21).